Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes

摘要

Downregulation of IL-6 (interleukin-6) signaling has been proposed as a strategy for lowering cardiovascular risk. Secondary analyses from CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) demonstrated that the therapeutic benefit of IL-1β (interleukin-1β) inhibition on cardiovascular prevention was associated with the reduction of IL-6 levels and that the residual cardiovascular risk was proportional to post-treatment IL-6 levels. Moreover, Mendelian randomization (MR) analyses showed variation in IL-6R (IL-6 receptor) gene ( ) to be associated with risk of coronary artery disease. Thus, directly interfering with IL-6 signaling might lower cardiovascular risk beyond IL-1β inhibition. Whether such an approach would be effective for ischemic stroke and other cardiovascular outcomes (aortic aneurysm, carotid plaque, peripheral artery disease, atrial fibrillation, heart failure, and thrombotic phenotypes) remains unknown.